Seeking a Cure for One of the Rarest Diseases: Progeria

Circulation

Volumn 134, Issue 2, 2016, Pages 126-129

  Collins, Francis S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Editorials; everolimus; lamin type A; lonafarnib; morpholinos; progeria; rare diseases; translational medical research

Indexed keywords

ENZYME; EVEROLIMUS; LAMIN A; LONAFARNIB; PRAVASTATIN; UNCLASSIFIED DRUG; ZMPSTE24 ENZYME; ZOLEDRONIC ACID;

BONE DENSITY; CHILD; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGERIA; RARE DISEASE; REVIEW; GENETICS; MUTATION;

HUMANS; LAMIN TYPE A; MUTATION; PROGERIA;

EID: 84978393967     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022965     Document Type: Review

References (20)

1. Online Mendelian Inheritance in Man. OMIM Gene Map Statistics. http://www.omim.org/statistics/geneMap. Accessed May 19, 2016.
2. National Institutes of Health. About NCATS, National Center for Advancing Translational Sciences. https://ncats.nih.gov/about. Accessed May 19, 2016.
3. Gordon LB, Kleinman ME, Massaro J, D'Agostino RB, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin and zoledronic acid in children with Hutchinson-Gilford Progeria Syndrome. Circulation. 2016;134:114-125. doi: 10.1161/CIRCULATIONAHA.116.022188.
4. Gordon LB, Cao K, Collins FS. Progeria: translational insights from cell biology. J Cell Biol. 2012;199:9-13. doi: 10.1083/jcb.201207072.
5. Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford progeria syndrome. GeneReviews® [Internet]. 2003, updated 2015.
6. Pagon, RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, eds. Seattle, WA: University of Washington, Seattle; 1993-2016.
7. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298. doi: 10.1038/nature01629.
8. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300:2055. doi: 10.1126/science.1084125.
9. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2012;109:16666-16671. doi: 10.1073/pnas.1202529109.
10. Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014;130:27-34. doi: 10.1161/CIRCULATIONAHA.113.008285.
11. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, Cadinanõs J, Osorio FG, Foray N, Cobo J, de Carlos F, Lévy N, Freije JM, López-Otín C. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14:767-772. doi: 10.1038/nm1786.
12. Progeria Research Foundation. Announcing The Progeria Research Foundation 8th International Scientific Workshop, May 2-4, 2016. http://progeriaresearch.org/prfs-2016-scientificworkshop/. Accessed May 19, 2016.
13. Gordon LB, Kieran MW, Kleinman ME, Misteli T. The decision-making process and criteria in selecting candidate drugs for progeria clinical trials [published online ahead of print May 26, 2016]. EMBO Mol Med. doi: 10.15252/emmm.201606280. http://embomolmed.embopress.org/content/early/2016/05/26/emmm.201606280.long. Accessed May 19, 2016.
14. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011;3:89ra58. doi: 10.1126/scitranslmed.3002346.
15. Progeria Research Foundation. New drug, new hope for children with progeria: phase 1, 2-drug trial begins April 2016. http://www.progeriaresearch.org/clinical-trial.html#fourCT. Accessed May 19, 2016.
16. Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med. 2005;11:440-445. doi: 10.1038/nm1204.
17. Lee JM, Nobumori C, Tu Y, Choi C, Yang SH, Jung HJ, Vickers TA, Rigo F, Bennett CF, Young SG, Fong LG. Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J Clin Invest. 2016;126:1592-1602. doi: 10.1172/JCI85908.
18. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125-140. doi: 10.1038/nrd3625.
19. Osorio FG, Navarro CL, Cadinanõs J, López-Mejiá IC, Quirós PM, Bartoli C, Rivera J, Tazi J, Guzmán G, Varela I, Depetris D, de Carlos F, Cobo J, Andrés V, De Sandre-Giovannoli A, Freije JM, Lévy N, López-Otín C. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011;3:106ra107. doi: 10.1126/scitranslmed.3002847.
20. Gordon LB, Rothman FG, López-Otín C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014;156:400-407. doi: 10.1016/j.cell.2013.12.028.